HOME >> MEDICINE >> NEWS
Headlines about Herceptin show equality of access to costly drugs must be tackled

The recent press coverage on the use of Herceptin (brand name for the drug trastuzumab) for treating breast cancer in its early stages shows that issues of equal access to costly but effective drugs must be confronted, says an editorial in this week's BMJ.

Trastuzumab was "rapidly adopted as the standard of care" in the US for treating breast cancer, but one of the barriers to its use in other countries is its high cost, say the authors. In Canada the treatment costs $C50,000 a year (25,000) per patient, and despite its effectiveness was not approved for funding in Ontario until after a media backlash.

The drug represents the first of probably many new cancer treatments of this kind, say the authors. The new hope it gives to patients also highlights new cost issues - both for the drugs themselves and surrounding cost of treatment.

Equality of patient access must extend to these accompanying areas, for example in diagnosing suitability for the drugs. Recent UK figures, for instance, show that only half of women are currently tested for the cancer gene targeted by the new treatment.

Healthcare systems around the world must no longer be left scrambling when effective new treatments come on the market. Transparent, timely and appropriately funded processes must be in place if patients are to get equal access to the best new treatments, conclude the authors.


'"/>

Contact: Tersea Hagan
thagan@bma.org.uk
44-207-383-6174
BMJ-British Medical Journal
3-Nov-2005


Page: 1

Related medicine news :

1. Medical residents unclear about TB guidelines
2. Threats to hope -- Desperation affects reasoning about product information
3. Men worry more about penile size than women, says 60-year-old research review
4. New mothers often not asked about depression, UNC survey finds
5. Smart mice teach scientists about learning process, brain disorders
6. Fatalistic beliefs about cancer cause many to ignore cancer prevention advice
7. Food and drink, and what it says about us
8. Forensic pathologists tell physiologists what they know about death and what puzzles them
9. Medical students should be taught about rape
10. Survey reveals misperceptions about Alzheimers among African-American and Hispanic caregivers
11. What do we know about asthma in Africa?

Post Your Comments:
(Date:5/29/2015)... Clarkston, Metamora, Michigan (PRWEB) May 29, 2015 ... vulvar region and can cause significant physical, sexual, and ... major life altering disorder of Vulvodynia. The actual diagnosis ... Women’s Excellence in Endometriosis, they realize that this problem ... patient is experiencing any of these symptoms, they need ...
(Date:5/29/2015)... CA (PRWEB) May 29, 2015 For the ... (USAU) to bring the Denver youth ultimate community an opportunity ... learning and individual improvement. The mission of the USAU Nike ... boys and girls to improve, build character, and make lifelong ... for boys and girls of all skill and ability levels, ...
(Date:5/29/2015)... External Counterpulsation, also known as EECP ... patients. The Heart Fit Clinic is the first clinic in ... review from patients who are now completing treatment. , ... treatments of ECP treatment and received great results. His ... does the clinic perform this non-surgical treatment for heart disease, ...
(Date:5/29/2015)... An organizational consultant and part-time college professor, Dr. ... and may be suffering from early dementia. He is ... and in his uncertain relationship with his wife Addie. ... with corporate and government movers and shakers as they ... around him are being diagnosed with Alzheimer’s, Ben wonders ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 Testosterone Centers of ... DFW area, is opening a new center in the Mid-Cities ... rest of the Mid Cities. Located on the south side ... in Hurst, the new testosterone center will open in May ... who suffer from low testosterone. , Like TCT’s other testosterone ...
Breaking Medicine News(10 mins):Health News:US Sports Camps, Nike Sports Camps, and USA Ultimate Host Third Summer of Ultimate Camp in Denver 2Health News:External Counterpulsation at Heart Fit Clinic Receives Raving Review 2Health News:‘Forgetful’ Professor Struggles With Dementia in Compelling New Novel 2Health News:Testosterone Clinics in Colleyville — TCT opens Hurst Location 2Health News:Testosterone Clinics in Colleyville — TCT opens Hurst Location 3
(Date:5/29/2015)... Lilly and Company (NYSE: LLY ) and AstraZeneca ... entered into a clinical trial collaboration to evaluate the ... checkpoint inhibitor, MEDI4736, in combination with CYRAMZA ® ... planned study will assess the combination as a treatment ... Phase I study is expected to establish the safety ...
(Date:5/28/2015)... 2015  Eli Lilly and Company (NYSE: LLY ) ... tender offer for up to $1.6 billion aggregate principal amount ... of notes who tendered, and did not validly withdraw, their ... City time, on May 27, 2015 (the early ... are eligible to receive the total consideration. The total consideration ...
(Date:5/28/2015)... 2015 Research and ... of Jain PharmaBiotech,s new report  "RNAi - ... offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... involves the use of double stranded RNA ... is processed into short 21-23 nucleotide RNAs ...
Breaking Medicine Technology:Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 2Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 3Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 4Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 5Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 6Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 7Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 8Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 9Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 10Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 11Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 12Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 13Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 14Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 3Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 4Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 5Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 2Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 3
Cached News: